DAB389EGF: Filed to begin Phase I/II trials

Seragen Inc. (SRGN) Product: DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxin Indication: Patients with solid malignancies that express the EGF receptor Status: Filed to begin P...